darunavir has been researched along with rilpivirine in 24 studies
| Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) | Studies (rilpivirine) | Trials (rilpivirine) | Recent Studies (post-2010) (rilpivirine) |
|---|---|---|---|---|---|
| 1,148 | 224 | 780 | 580 | 93 | 513 |
| Protein | Taxonomy | darunavir (IC50) | rilpivirine (IC50) |
|---|---|---|---|
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 0.068 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 6.1612 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 1.7406 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 2.3635 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 0.2818 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 0.3363 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.5 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 0.0759 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.33) | 29.6817 |
| 2010's | 14 (58.33) | 24.3611 |
| 2020's | 8 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Botta, M; Dasso Lang, MC; De Forni, D; Friggeri, L; Giannini, A; Kovalenko, L; Malancona, S; Mely, Y; Mori, M; Palombi, N; Poddesu, B; Saladini, F; Summa, V; Zazzi, M | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Susman, E | 1 |
| Arastéh, K; Müller, M | 1 |
| Lacombe, K; Surgers, L | 1 |
| Alegre, F; Apostolova, N; Blas-García, A; Esplugues, JV; Funes, HA; Martínez, E; Polo, M | 1 |
| Callegaro, A; Di Filippo, E; Maggiolo, F; Serna Ortega, PA; Valenti, D | 1 |
| Acosta, EP; Britto, P; Carey, VJ; Cressey, TR; Foca, M; Graham, B; Hazra, R; Jean-Philippe, P; King, J; Wiznia, A; Yogev, R | 1 |
| Ascione, T; Boccia, G; Carleo, MA; De Caro, F; Pagliano, P; Tortora, F | 1 |
| Cattaneo, D; Clementi, E; Cozzi, V; Galli, M; Gervasoni, C; Meraviglia, P; Minisci, D; Riva, A | 1 |
| Bayés-Genís, A; Blanco, J; Bonjoch, A; Clotet, B; Echeverría, P; Gómez-Mora, E; Negredo, E; Pérez-Alvarez, N; Puig, J; Roura, S | 1 |
| Back, D; Boffito, M; Devitt, E; Else, L; Higgs, C; Jackson, A; Karolia, Z; Khoo, S; Pozniak, A | 1 |
| Boswell, R; Foisy, MM; Hughes, CA | 1 |
| Álvarez, H; Llibre, JM; Yzusqui, M | 1 |
| Arazo, P; Carmena, J; Crusells, MJ; de Jesus, SE; de la Torre, J; Galindo, MJ; Hidalgo-Tenorio, C; Lozano, F; Palacios, Z; Pasquau, J; Ríos, MJ; Samperiz, G; Santos, J; Tornero, C; Verdejo, G | 1 |
| Dunn, KJ; Kagan, RM; Kaufman, HW; Nettles, RE; Snell, GP | 1 |
| Castagna, A; Comi, L; Di Filippo, E; Fumagalli, L; Galli, L; Gianotti, N; Maggiolo, F; Nozza, S; Rizzi, M; Valenti, D | 2 |
| Bernardino, JI; Casado, JL; Colomer, J; Curran, A; Domingo, P; González-Cordón, A; Llibre, JM; Martínez, E; Navarro, J; Portilla, J; Rial-Crestelo, D; Ribera, E; Vizcarra, P | 1 |
| Bonnet, F; Burkholder, G; Castagna, A; Cavassini, M; Cichon, P; Crane, H; Domingo, P; Gill, MJ; Grabar, S; Guest, J; Ingle, SM; Obel, N; Psichogiou, M; Rava, M; Reiss, P; Rentsch, CT; Riera, M; Sabin, CA; Schuettfort, G; Silverberg, MJ; Smith, C; Stecher, M; Sterling, TR; Sterne, JAC; Trickey, A; Zhang, L | 1 |
| Brummel, SS; Chadwick, EG; Huo, Y; Jacobson, DL; Jao, J; Kacanek, D; Kahlert, CR; Patel, K; Powis, KM; Seage, GR; Shiau, S; Sultan-Beyer, L; Williams, PL; Yee, LM; Zash, R | 1 |
| Byakika-Kibwika, P; Chappell, CA; Fletcher, CV; Jeppson, J; Kaboggoza, J; Kyohairwe, I; Lamorde, M; Mbabazi, L; Musaazi, J; Nakalema, S; Nakijoba, R; Nassiwa, S; Pham, M; Scarsi, KK; Siccardi, M; Walimbwa, SI; Winchester, L | 1 |
| Aebi-Popp, K; Crisinel, PA; Decosterd, L; Duppenthaler, A; Hoesli, I; Kahlert, CR; Martinez De Tejada, B; Marzolini, C; Rauch, A; Saldanha, SA | 1 |
3 review(s) available for darunavir and rilpivirine
| Article | Year |
|---|---|
Hepatoxicity of new antiretrovirals: a systematic review.
Topics: Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Cyclohexanes; Darunavir; Heterocyclic Compounds, 3-Ring; Humans; Maraviroc; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Rilpivirine; Sulfonamides; Triazoles | 2013 |
Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review.
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Observational Studies as Topic; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Rilpivirine | 2018 |
Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review
Topics: Amides; Anti-Retroviral Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine; RNA, Viral; Triazoles; Viral Load | 2018 |
3 trial(s) available for darunavir and rilpivirine
| Article | Year |
|---|---|
NRTI Sparing Therapy in Virologically Controlled HIV-1 Infected Subjects: Results of a Controlled, Randomized Trial (Probe).
Topics: CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HLA-DR Antigens; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Viral Load | 2016 |
Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2).
Topics: Adenine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Pharmaceutical Preparations; Rilpivirine; Treatment Outcome; Viral Load | 2020 |
Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial.
Topics: Adult; Cobicistat; Darunavir; HIV Infections; HIV-1; Humans; Pharmaceutical Preparations; Rilpivirine; RNA; United States; Viral Load | 2021 |
18 other study(ies) available for darunavir and rilpivirine
| Article | Year |
|---|---|
Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein.
Topics: | 2019 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
HIV Pathogenesis and Treatment - Third International AIDS Society Conference.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Chemistry, Pharmaceutical; Clinical Trials as Topic; Congresses as Topic; Darunavir; Drugs, Investigational; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Peptide Fragments; Pyrimidines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Rilpivirine; Societies, Scientific; Sulfonamides; Tenofovir; Zalcitabine | 2005 |
[New drugs--hope for salvage patients?].
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Drugs, Investigational; HIV Infections; HIV Integrase Inhibitors; Humans; Nitriles; Pyrimidines; Receptors, Chemokine; Rilpivirine; Salvage Therapy; Sulfonamides; Treatment Failure | 2005 |
[HIV therapy of the next generation. Modern active drugs for long-term treatment].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Investigational; HIV Infections; Humans; Long-Term Care; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Sulfonamides | 2012 |
Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz.
Topics: Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line, Tumor; Cells, Cultured; Cyclopropanes; Darunavir; Drug Resistance, Viral; Hepatocytes; Humans; Mitochondria; Neurons; Nitriles; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Rats; Reverse Transcriptase Inhibitors; Rilpivirine; Sulfonamides | 2014 |
Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Rilpivirine; Ritonavir; Young Adult | 2016 |
HIV positive patient with HSV-2 encephalitis: case report.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Substitution; Encephalitis, Herpes Simplex; Herpesvirus 2, Human; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Rilpivirine; Ritonavir; Virus Replication | 2016 |
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
Topics: Anti-HIV Agents; Atazanavir Sulfate; Biological Availability; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Viral Load | 2017 |
Variable endothelial cell function restoration after initiation of two antiretroviral regimens in HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Darunavir; Endothelial Cells; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Reverse Transcriptase Inhibitors; Rilpivirine; Viral Load; Viremia | 2017 |
Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Rilpivirine; Ritonavir; Viral Load; Young Adult | 2018 |
Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study).
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Darunavir; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Rilpivirine; Treatment Outcome; Viral Load | 2019 |
Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
Topics: Anti-HIV Agents; Darunavir; Dideoxynucleosides; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2019 |
Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study.
Topics: Anti-HIV Agents; Darunavir; HIV Infections; HIV-1; Humans; Retrospective Studies; Rilpivirine; Ritonavir; Spain; Viral Load | 2020 |
Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Europe; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; North America; Raltegravir Potassium; Rilpivirine | 2022 |
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Oxazines; Piperazines; Pregnancy; Premature Birth; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Ritonavir; United States | 2022 |
Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy.
Topics: Contraceptive Agents; Darunavir; Female; HIV Infections; Humans; Levonorgestrel; Progestins; Rilpivirine; Ritonavir | 2022 |
Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cohort Studies; Darunavir; Female; HIV Infections; Humans; Infant; Milk, Human; Mothers; Prospective Studies; Raltegravir Potassium; Rilpivirine; Ritonavir; Switzerland | 2022 |